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Childhood tuberculosis (TB) has increasingly been recognised as 
contributing a substantial proportion of the global TB caseload. 
In South Africa childhood TB has been estimated to contribute 
approximately 20% of all cases, with the most recent estimates of TB 
prevalence in Cape Town of 511/100 000 in children under 5 years 
of age.1 The resurgence in TB incidence has been driven by the HIV 
epidemic, with dual epidemics occurring in South Africa.  
In recent decades there have been advances in several areas of 
childhood TB with much research conducted at the University of 
Cape Town. Pioneering work has been done spanning diagnosis, 
prevention, management and the impact of HIV. This article reviews 
some of these recent advances.  
Advances in epidemiology
The highest TB incidence rates in the world occur in sub-Saharan 
African countries, many of which are also experiencing an HIV 
epidemic.2 TB is a leading cause of mortality and morbidity in South 
Africans generally. While adult TB results from both recent and past 
infection, childhood TB results from recent infection and reflects 
on-going TB transmission.3 Pulmonary TB (PTB) is an important 
cause of morbidity and death in African children. TB in children 
frequently occurs in association with HIV infection.  The rates of 
TB infection now found in South African children and adolescents 
are similar to those reported in Europe before chemotherapy became 
available. Mycobacterium tuberculosis is increasingly reported as an 
important cause of acute pneumonia among children from high 
TB prevalence areas,4 including South African children, both HIV-
infected and uninfected.5  
An important study by Middelkoop et al.3 in Cape Town township 
children under 15 years reported a 4% annual risk of infection 
and an annual TB notification rate of 0.6 - 1.0%. The mean 
percentage of exposures to adult TB for TB-uninfected children, 
latently TB-infected children and TB cases was 5.1%, 5.4% and 33% 
per annum and the mean number of adult smear-positive cases 
per exposed child was 1.0, 1.6 and 1.9, respectively. Acquisition of 
infection was not associated with the HIV status of the adult TB case 
to which the child was exposed; 36% of paediatric TB cases were 
diagnosed before the temporally closest adult case on their plot. They 
also demonstrated that the annual risk of TB infection in preschool 
children predominantly results from infectious residents at home, but 
that even with limited social interactions, much transmission occurs 
from non-resident adults. Reductions in household transmission 
could be achieved by increasing ventilation or by separating child and 
adult sleeping areas.6
Some important insights into the epidemiology of paediatric TB in 
high prevalence settings have also been gained through trials of novel 
TB vaccines.7 Mahomed et al.8 reviewed the clinical records of all 
children under 2 years of age diagnosed with TB disease in the greater 
Cape Town area who were born during a change in the vaccination 
programme from percutaneous (PC) Tokyo to intradermal (ID) 
Danish BCG. The annual incidence rate of 0.86 - 0.87% was similar 
for PC and ID recipients. However, the rate of disseminated TB was 
significantly lower in the ID cohort and significantly higher in those 
not vaccinated with bacilli Calmette-Guérin (BCG).8 Further analysis 
showed that TB incidence peaked in children aged 12 - 23 months, 
with many children experiencing severe TB disease; 20% of children 
with microbiologically confirmed TB presented with only one feature 
typically associated with TB.9
Hawkridge et al.10 in a phase IV trial comparing the efficacy of PC 
versus ID Tokyo BCG in the prevention of TB in 11 680 newborns, 
demonstrated equivalence between the groups, and reported very 
high disease rates. From the same trial, Hatherill et al.11 demonstrated 
poor agreement and high variability between structured approaches 
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(‘scoring systems’) used for the screening and diagnosis of childhood 
TB for case yield. TB infection and disease rates in adolescents have 
also been studied as part of preparation for TB vaccine trials in this 
target population. In the Boland rural area between 40% and 60% of 
13 - 18-year-olds were found to be infected, as indicated by a positive 
tuberculin skin test or an interferon-gamma release assay;12 the 
annual risk of infection was approximately 3%. Disease rates, around 
0.4% per annum, depending on the case definition used, appear to be 
lower than in infants (H Mahomed, personal communication).
Advances in diagnosis
PTB in children may be difficult to diagnose definitively as a 
result of nonspecific clinical and radiological signs, paucibacillary 
disease, and lack of capacity for microbiological diagnosis. Diagnostic 
uncertainty has been compounded by the HIV epidemic in which 
chronic lung disease, anergy and nonspecific clinical and radiological 
signs make definitive diagnosis even more challenging. While the 
clinical diagnosis has relied on chronic symptoms such as prolonged 
coughing or failure to thrive, recent studies have shown that TB is a 
cause of acute pneumonia (rather than chronic disease). In a study of 
children hospitalised with acute pneumonia in Cape Town, culture-
confirmed TB occurred in 8% of HIV-infected and -uninfected 
children.13 Clinical or radiological signs do not enable PTB to be 
distinguished from other pathogens. Radiological changes may be 
nonspecific and interpretation is further complicated by wide inter- 
and intra-observer variation in the interpretation of the presence of 
mediastinal lymphadenopathy, one of the major radiological features 
for diagnosis.14,15 
Immunological diagnosis 
Interferon-gamma release assays (IGRAs)
The diagnostic usefulness of IGRAs in settings characterised by 
high TB and HIV infection rates was explored in several studies. 
Either enzyme-linked immunospot (ELISPOT) or Quantiferon 
TB Gold (in-tube) assays were utilised in these studies. An early 
project in hospitalised children recorded detectable ELISPOT 
responses to ESAT-6 or CFP10 in 49 of 70 (70%) children with 
clinical TB. Detectable responses were most frequent in children 
with culture-confirmed disease, i.e.10 of 12 children (83.3%).16 
Subsequent community-based studies showed that the performance 
of IGRAs was not superior to that of tuberculin skin tests (TSTs) 
for diagnosing childhood TB. The first of these studies evaluated 
the T-SPOT.TB assay, a commercial ELISPOT test in 218 children 
with a median (interquartile range) age of 18 (14 - 24) months. The 
sensitivity of T-SPOT.TB was not statistically different from that 
of TST in culture-confirmed TB, and T-SPOT.TB performed more 
poorly when evaluated in all children with culture-confirmed and 
probable TB (40% v. 52%).17 Another study in 397 children less 
than 3 years of age yielded similar sensitivities and specificities 
for the Quantiferon TB Gold (in-tube) assay and TST, with very 
good agreement between these tests.18 A similar study performed 
in adolescents showed that there was no significant difference in 
the diagnostic predictive value of Quantiferon TB Gold (in-tube) 
assay and TST.12     
In HIV-infected children with culture-confirmed or probable 
TB, ELISPOT was shown to be more sensitive than TST for the 
detection of active TB, i.e. 25/39 (64%) v. 10/34 (29%), p=0.005. 
The sensitivity of ELISPOT in HIV-infected children was not high 
enough for the test to be used to rule out TB.19 Extended analysis of 
this dataset showed that beyond clinical findings, ELISPOT did not 
have statistically significant added diagnostic value in HIV-infected 
children with smear-negative TB.
In summary, these studies showed that there is a very limited role 
for IGRAs in the routine investigation of childhood TB in high-
burden settings. Additional study in HIV-infected children may be 
warranted.
Tuberculin skin testing 
A study of more than 1 500 children <5 years old who underwent 
tuberculin skin testing with both Mantoux and Tine tests showed that 
a significantly higher proportion tested positive on Tine testing (32.8% 
v. 28.4%) with reasonable agreement between the two testing methods. 
These findings suggested that the Tine test should be considered as 
a screening tool for childhood TB in resource-limited settings.20 
Although several factors are known to influence TST response, 
including nutritional status, HIV infection, immunosuppressive 
therapy and severe primary immunodeficiencies, whether or not 
genetic determinants influence the response was not known until 
very recently. An international research collaborative explored this 
question by conducting a genome-wide linkage search for loci 
affecting TST reactivity in a large Western Cape patient cohort. 
Two gene loci controlling TST reactivity were identified, located on 
chromosomal regions 11p14, which influences T-cell independent 
resistance to M. tuberculosis and 5p15 which controls the intensity 
of T-cell-mediated delayed hypersensitivity to tuberculin. These 
findings are considered important, because further exploration of 
these gene loci may help to elucidate the molecular mechanisms 
involved in resistance to M. tuberculosis in high TB prevalence 
settings.21 
Microbiological diagnosis
Definitive microbiological diagnosis and antimicrobial susceptibility 
have become increasingly important for reliable diagnosis in children, 
given the issues of pill burden, adherence and the emergence of drug-
resistant isolates.22 Microbiological confirmation of TB in children 
by culture has not been part of routine care in high-burden settings, 
because of the unavailability of facilities, the difficulty in obtaining 
samples, the poor performance of smear microscopy and the 
perception that microbiological yield is low. However, several studies 
done in Cape Town have confirmed the feasibility and usefulness 
of microbiological confirmation in young children with suspected 
PTB using sputum induction.23-28 These have shown that collection 
of sputum is feasible, safe and effective even in infants. Sputum 
induction has a number of advantages over gastric lavage (GL) as it 
can be done as an outpatient procedure, is relatively easy to perform, 
and the yield is higher. In two large studies in hospitalised infants in 
a tertiary care facility in South Africa (median ages 9 and 13 months), 
samples were successfully obtained from 95% of children.23,27 In the 
first study, one induced sputum (IS) sample yielded more positive 
cultures (10% of samples) than 3 sequential GL samples (6% of 
samples).23 In the second study the cumulative yield from 3 IS 
samples (87%) was greater than that of 3 GL samples (65%, p=0.018), 
while a single IS sample was equivalent to three GL samples.27 The 
yield was similar in HIV-infected and -uninfected children.
Two studies in the Western Cape have evaluated the yield from 
sputum induction in less ill children presenting for care at primary 
or secondary level health facilities.25,26 Among children with mild 
illness admitted to a case-verification ward as part of an infant TB 
vaccine trial, the yield of a single IS and GL sample was equivalent; 
however, positive cultures (from 2 GL and 2 IS samples) were only 
obtained in 10% of children admitted.25  More recently a study done 
at a primary care clinic in Khayelitsha, investigated  270 children 
(median age 38 months) with suspected TB with 2 IS specimens 
taken on sequential days. In 11% of cases, a microbiological diagnosis 
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was made; furthermore IS improved the diagnostic yield by 22%, 
resulting in substantial numbers of children receiving treatment who 
would not have been treated on clinical judgement.26  Furthermore, 
using a Likert scale, most sputum induction procedures (91%) 
were rated as very easy or easy to perform by the healthcare worker 
performing the test in this setting.26 Combined data from a number of 
studies in infants and young children involving thousands of sputum 
induction procedures have found IS to be safe without any serious 
adverse events.23-28
For prompt, effective initiation of therapy, a rapid diagnosis of TB 
in children is needed. Most recently, IS was reported to be highly 
effective for rapid detection of PTB including rifampicin resistance 
using Xpert MTB/RIF, an integrated specimen processing and 
nucleic acid amplification test for detection of M. tuberculosis and of 
resistance to rifampicin. In this study, Xpert done on two sequential 
sputum specimens detected 76% of children with culture-confirmed 
disease with 99% specificity; the yield was more than twice that 
of a smear.28 Detection of rifampicin resistance was highly reliable 
compared with line probe assay. Results, available at a median of 1 
day, were much faster than culture.28 These results have provided 
evidence in children to support the recent recommendations by the 
World Health Organization (WHO) that Xpert should replace smear 
on sputum specimens as the initial diagnostic test in areas of high 
HIV prevalence or drug resistance.29
The reliability of Xpert is an important advance, enabling rapid 
diagnosis of childhood TB and initiation of appropriate therapy. 
This is important as South African studies have reported that up 
to 50% of children who have culture-confirmed TB are discharged 
from health facilities without treatment as culture results take weeks. 
However, upscaling of capacity for sputum induction for children 
in health facilities is needed, including appropriate training of staff. 
The tools now exist for better diagnosis of childhood TB but the 
operationalisation of this will depend on visionary policy makers, 
health managers and healthcare workers.   
Prevention of TB disease
Prevention of TB disease may be achieved through a number 
of strategies including improvement in socio-economic living 
conditions, better TB control especially detection of adult cases, 
immunisation of children, use of isoniazid (INH) prophylaxis and 
use of highly active antiretroviral therapy (HAART) in HIV-infected 
children. Much work on understanding the immunological response 
to M. tuberculosis infection and developing improved TB vaccine 
strategies has been done by the South African TB Vaccine Initiative 
(SATVI), which is addressed in a separate publication. The use of 
primary INH prophylaxis in HIV-infected children is an effective 
strategy that has been studied in Cape Town. 
INH prophylaxis
National and international guidelines have consistently recommended 
INH prophylaxis given for 6 months in children under 5 years of age 
or HIV-infected children of any age, who are exposed to a household 
TB contact or have a positive tuberculin skin test.    
Recently, the efficacy and safety of primary INH prophylaxis in 
HIV-infected children has been shown in a randomised control trial 
done in Cape Town. In this study, children receiving INH had a 
significant reduction in TB incidence and in mortality. INH reduced 
the incidence of TB by 72% and mortality by 54%.30 Of note, most 
children were not taking HAART at the start of the study, which 
pre-dated antiretroviral availability in South Africa. More recently, a 
follow-up study of this cohort reported the efficacy of INH in addition 
to HAART for TB prevention. Children were followed up for a median 
of 5 years, during which most went onto HAART. Over this time 
HAART reduced the incidence of culture-confirmed TB by 70%, INH 
alone reduced this by 80% while the combination of INH and HAART 
was most effective, reducing TB incidence by 90%.31 In contrast, INH 
prophylaxis has not been reported to be effective for preventing TB in 
HIV-exposed infants who were initiated on HAART early in life and 
were very closely followed up, including provision of INH prophylaxis 
whenever there was exposure to a household TB contact.32  Differences 
in patient populations (clinically well HIV-exposed infants with mild 
immunosuppression started on HAART32 compared with HIV-infected 
children with advanced clinical and immunological disease30,31) and 
study methodology, particularly very consistent and reliable use of 
INH prophylaxis for HIV-exposed children if there was contact with 
an adult TB source case, may explain these findings.33 In reality, tracing 
of child contacts is notoriously poorly done in TB programmes, so 
this strategy is unlikely to be feasible in high TB prevalence countries; 
moreover, this cannot be applied to children with more advanced HIV 
disease. Excellent long-term safety has been reported with such use of 
INH prophylaxis.34    
Thus INH may be an effective public health intervention for HIV-
infected children living in high TB prevalence areas, especially in 
children with more advanced HIV disease.35 Recent WHO guidelines 
now recommend primary INH prophylaxis in adults, adolescents and 
HIV-infected children over 1 year of age living in high TB prevalence 
areas for up to 36 months.36   
Tuberculous meningitis 
Tuberculous meningitis (TBM) is the most lethal form of TB, yet 
little progress has been made in therapy. Several controversies 
remain, including the treatment of increased intracranial pressure 
and tuberculous hydrocephalus. Although computed tomography 
is essential, it cannot determine intracranial pressure or distinguish 
between communicating and non-communicating hydrocephalus.37 
This is critical to directing further therapy. Standard surgical treatment 
for hydrocephalus has been ventriculoperitoneal shunt insertion, 
but long-term complications are common. As an alternative, we 
described the use of endoscopy for non-communicating tuberculous 
hydrocephalus, a procedure in which the cerebrospinal fluid is drained 
internally, without relying on an external shunt.38 We reported the 
endoscopic features of ependymal tubercles, thickened and inflamed 
hypothalamus, and extensive exudates in the prepontine cistern, and 
a protocol for managing these difficult patients.39 Subsequent to the 
original description, several other centres have reported the use of 
endoscopy for tuberculous hydrocephalus. 
Even if increased intracranial pressure is successfully treated, 
however, patients often die or are disabled by the vasculitis of the 
basal cerebral vessels and consequent brain infarction. There have 
been no methods to diagnose this ischaemic process or interventions 
to prevent it; radiology simply confirms the end result. Recently we 
demonstrated how brain oxygen monitoring could be used to detect 
ischaemia in these patients, raising the possibility of being able to 
intervene before infarction ensues.40 Since brain ischaemia leads to 
death and disability, we need to develop better invasive and non-
invasive tools to enable monitoring for ischaemia. 
There are major obstacles to determining which patients will 
deteriorate: the clinical features are nonspecific, several factors 
may be operative, including increased intracranial pressure, brain 
ischaemia, encephalopathy, seizures, and hyponatraemia. Therefore, 
we have embarked on a study to examine biological markers of the 
degree of inflammation and structural brain injury that may yield an 
objective measure of disease severity and a possible surrogate marker 
for evaluating subsequent treatment interventions.
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Conclusion
There have been major advances in the development of better 
diagnostic, treatment and preventive strategies for childhood TB. 
Prevailing perceptions that a confirmed diagnosis is difficult or 
unnecessary need to change as widespread implementation of new 
diagnostic testing and of appropriate treatment in children can 
potentially be achieved. However, under-recognition of the disease 
burden and a relative lack of resources for childhood TB remain 
challenging. 
References 
1. Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, Bekker LG. Burden of new and recurrent 
tuberculosis in a major South African city stratifed by age and HIV-status. PLoS One 2011;6(10):e25098.
2. Zar HJ. Global paediatric pulmonology: out of Africa. Paediatr Respir Rev 2006;7 Suppl 1:S226-228.
3. Middelkoop K, Bekker LG, Morrow C, Zwane E, Wood R. Childhood TB infection and disease: a 
spatial and temporal transmission analysis in a South African township. S Afr Med J 2009;99(10):738-
743..
4. Zar HJ. Pneumonia in HIV-infected and HIV-uninfected children in developing countries: 
epidemiology, clinical features, and management. Curr Opin Pulm Med 2004;10(3):176-182.
5. Gray DM, Zar HJ. Community-acquired pneumonia in HIV-infected children: a global perspective. 
Curr Opin Pulm Med 2010;16(3):208-216. 
6. Wood R, Johnstone-Robertson S, Uys P, et al. TB transmission to young children in a South African 
community: modeling household and community infection risks. Clin Infect Dis 2010;51(4):401-418. 
7. Hussey G, Hawkridge T, Hanekom W. Childhood TB: old and new vaccines. Paediatr Respir Rev 
2007;8(2):148-154.
8. Mahomed H, Kibel M, Hawkridge T, et al. The impact of a change in bacilli Calmette-Guérin vaccine 
policy on TB incidence in children in Cape Town, South Africa. Pediatr Infect Dis J 2006;25(12):1167-
1172. 
9. Moyo S, Verver S, Mahomed H, et al. Age-related TB incidence and severity in children under 5 years 
of age in Cape Town, South Africa. Int J Tuberc Lung Dis 2010;14(2):149-154. 
10. Hawkridge A, Hatherill M, Little F, et al. Efficacy of percutaneous versus intradermal BCG in the 
prevention of TB in South African infants: randomised trial. BMJ 2008;337:a2052.
11. Hatherill M, Hanslo M, Hawkridge T, et al. Structured approaches for the screening and diagnosis of 
childhood TB in a high prevalence region of South Africa. Bull World Health Organ 2010;88(4):312-
320. Epub 29 Dec 2009. 
12. Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold® 
in predicting TB disease in an adolescent cohort study in South Africa. PLoS One 2011;6(3):e17984.
13. Zar HJ, Hanslo D, Tannenbaum E, et al.  Aetiology and outcome of pneumonia in human 
immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatr 2001;90(2):119-
125.
14. Swingler GH, du Toit G, Andronikou S, van der Merwe L, Zar HJ. Diagnostic accuracy of chest 
radiography in detecting mediastinal lymphadenopathy in suspected pulmonary TB. Arch Dis Child 
2005;90:1153-1156.
15. Andronikou S, Brauer B, Galpin J, et al. Interobserver variability in the detection of mediastinal and 
hilar lymph nodes on CT in children with suspected pulmonary TB. Pediatr Radiol 2006;36(4):368.
16. Nicol M, Pienaar D, Wood K, et al. Enzyme-linked immunospot assay responses to early secretory 
antigenic target 6, culture filtrate protein10, and purified protein derivative among children with TB: 
implications for diagnosis and monitoring of therapy. Clin Infect Dis 2005;40:1301-1308.
17. Nicol MP, Davies MA, Wood K, et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the 
evaluation of young children at high risk for TB in a community setting. Pediatrics 2009; 123:38-43.
18. Moyo S, Isaacs F, Gelderbloem S, et al. Tuberculin skin test and QuantiFERON® assay in young 
children investigated for TB in South Africa. Int J Tuberc Lung Dis 2011;15:1176-1181.
19. Davies M, Connell T, Johannisen C, et al. Detection of TB in HIV-infected children using an enzyme-
linked immunospot assay. AIDS 2009; 23:961-969.
20. Pan W, Matizirofe L, Workman L, et al. Comparison of Mantoux and Tine tuberculin skin tests in 
BCG-vaccinated children investigated for TB. PloS One 2009;4(11):e8085.
21. Cobat A, Gallant CJ, Simkin L, et al. Two loci control tuberculin skin test reactivity in an area 
hyperdemic for TB. J Exp Med 2009;206:2583-2591.
22. Connell TG, Zar HJ, Nicol MP. Advances in the diagnosis of pulmonary TB in HIV-infected and HIV-
uninfected children. J Infect Dis 2011;204:S1151-1158.
23. Zar HJ, Tannenbaum E, Apolles P, Roux P, Hanslo D, Hussey G. Sputum induction for the diagnosis 
of pulmonary TB in infants and young children in an urban setting in South Africa. Arch Dis Child 
2000;82(4):305-308. 
24.  Zar HJ, Tannenbaum E, Hanslo D, Hussey G. Sputum induction as a diagnostic tool for community-
acquired pneumonia in infants and young children from a high HIV prevalence area. Pediatr 
Pulmonol 2003;36(1):58-62.
25. Hatherill M, Hawkridge T, Zar HJ, et al. Induced sputum or gastric lavage for community-based 
diagnosis of childhood pulmonary TB? Arch Dis Child 2009;94(3):195-201.
26. Moore H, de Villers PJT, Apolles P, Zar HJ. Sputum induction for diagnosis of childhood pulmonary 
TB (PTB) in a community setting. Int J Tuber Lung Dis (in press).
27. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for 
microbiological confirmation of pulmonary TB in infants and young children: a prospective study. 
Lancet 2005;365:130-134.
28. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of 
pulmonary TB in hospitalized children in a high HIV-prevalence area. Lancet Infect Dis 2011;Jul 15.
29. World Health Organization (WHO). Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis 
of TB and MDR-TB, 6 December 2010. Geneva: WHO, 2010. Available at: http://www.who.int/tb/
laboratory/roadmap_xpert_mtb-rif.pdf (accessed 4 December 2011). 
30. Zar HJ, Cotton MF, Strauss S, et.al. Effect of isoniazid prophylaxis on mortality and incidence of TB in 
children with HIV: randomized controlled trial. BMJ 2007;334:136. 
31. Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard C, Zar HJ. The impact of isoniazid prophylaxis 
and antiretroviral therapy on TB in children infected with HIV in a high TB incidence setting. Thorax 
2011;66(6):496-501.
32. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against TB in HIV-exposed 
children. N Engl J Med 2011:365:21-31.
33. Zar HJ, Lombard C. Isoniazid prophylaxis against TB in children. N Engl J Med 2011;365(16):1543.
34. Gray D, Nuttall J, Lombard C, et al. Low rates of hepatotoxicity in hiv-infected children on anti-
retroviral therapy with and without isoniazid prophylaxis. J Trop Pediatr 2010:56(3):159-165. 
35. Gray DM, Zar H, Cotton M. Impact of TB preventive therapy on TB and mortality in HIV-infected 
children. Cochrane Database Syst Rev 2009;(1):CD006418. 
36. WHO 2011 Guidelines for intensified TB case finding and INH preventive therapy for people living 
with HIV in resource constrained settings www.who.int/tb (accessed December 2011).
37. Figaji AA, Fieggen AG, Peter JC. Air encephalography for hydrocephalus in the era of neuroendoscopy. 
Childs Nerv Syst 2005;21:559-565. 
38. Figaji AA, Fieggen AG, Peter JC. Endoscopic third ventriculostomy in tuberculous meningitis. Childs 
Nerv Syst 2003;19:217-225. 
39. Figaji AA, Fieggen AG, Peter JC. Endoscopy for tuberculous hydrocephalus. Childs Nerv Syst 
2007;23:79-84. 
40. Figaji AA, Sandler SJ, Fieggen AG, le Roux PD, Peter JC, Argent AC. Continuous monitoring and 
intervention for cerebral ischemia in tuberculous meningitis. Pediatr Crit Care Med 2008;9:e25-e30. 
Accepted 31 January 2012.
